20/20 Biolabs (NASDAQ:AIDX) Issues Quarterly Earnings Results

20/20 Biolabs (NASDAQ:AIDX) posted its quarterly earnings results on Wednesday. The company reported ($0.28) EPS for the quarter, FiscalAI reports. The business had revenue of $0.35 million for the quarter.

20/20 Biolabs Stock Down 6.6%

Shares of NASDAQ:AIDX opened at $1.21 on Friday. 20/20 Biolabs has a twelve month low of $1.19 and a twelve month high of $50.00. The business’s 50 day moving average is $1.74.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Maxim Group assumed coverage on shares of 20/20 Biolabs in a report on Monday, May 11th. They set a “buy” rating and a $5.00 price target for the company. Wall Street Zen upgraded shares of 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. Finally, Weiss Ratings assumed coverage on shares of 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.